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[571 ABSTRACT 
Artificial high-fidelity three-dimensional human urogenital 
tract carcinomas are propagated under in vitro-microgravity 
conditions from carcinoma cells. Artificial high-fidelity 
three-dimensional human urogenital tract carcinomas are 
also propagated from a coculture of normal urogenital tract 
cells inoculated with carcinoma cells. The microgravity 
culture conditions may be microgravity or simulated micro- 
gravity created in a horizontal rotating wall culture vessel. 
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CULTURED HIGH-FIDELITY THREE- 
DIMENSIONAL HUMAN UROGENITAL 
TRACT CARCINOMAS AND PROCESS 
RELATED PATENTS AND APPLICATIONS 
5,851,816 
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mammalian cells frequently require that the cells attach 
themselves to some substrate surface to remain viable and to 
duplicate. The particular culture requirements of mamma- 
lian cells make successful in vitro culturing of both normal 
s and neoplastic tumorous mammalian cells difficult. 
The present case is a continuation-in-part of u,s, patent Futue S~CCeSSeS in cancer therapy are dependent upon 
application Ser, No, 071939,791, filed Sep, 3, 1992, entitled therapeutic testing in that tumorous 
“Three-Dimensional Coculture Process,,, now u,s, Pat, No, tissue in situ. Although several human carcinoma cell lines 
Ser, No, 071317,931, filed Mar, 2, 1989, entitled “Three- 10 researchers to study and characterize various aspects of 5,308,764, issued May 3, 1994, which is a continuation of 
have been propagated for many years, thereby 
Dimensional Coculture Process”, now U,S, Pat, No, 5,153, 
132, issued Oct, 6, 1992, which is a continuation-in-part of reproducib1e Of in 
genesis, present in vitro does not permit 
Ser, No, 317,776, filed Mar, 2, 1989, entitled “Three Dimen- three-dimensional configuration. The culture of most neo- 
sional Cell and Tissue Assembly Process,,, now u,s, Pat, plastic cells has a low success rate, with low percentages of 
No, 5,155,034, issued Oct, 13, 1992, which is a 15 neoplastic cells being established in vitro. 
continuation-in-part of Ser. No. 213,558, filed Jun. 30,1988, Three-dimensional in vitro tumor models are intermediate 
now U.S. Pat. No. 5,026,650, issued Jun. 25, 1991, entitled in complexity between standard two-dimensional monolayer 
~ ~ H o r i z o n t a ~ ~ y  Rotated cell Culture System with a coaxial cultures in vitro and tumors in vivo. In vitro cultured 
Tubular Oxygenator” and ser, N ~ ,  213,559, filed juri, 30, three-dimensional tumors demonstrate overall growth char- 
1988, now u,s, pat, No, 4,988,623, issued Jan, 29, 1991, ’’ acteristics similar to those of tumors in vivo. The techniques 
“Rotating Bio-Reactor cell Culture Apparatus”, and developed for producing in vitro three-dimensional tumor 
Ser. No. 625,345, filed Dec. 11, 1990, now U.S. Pat. No. cell aggregates to mimic in Vivo tumor cell growth, however, 
5,153,131, issued Oct. 6, 1992, entitled “High Aspect Reac- have been found to have many limiting aspects. 
tor Vessel and Method of Use”, all of which are specifically 25 High-density, three-dimensional in vitro growth of mam- 
incorporated by reference as if fully set forth herein. U.S. malian tumor cells is problematic due to the effects of shear, 
patent application Ser. No. 081066,292, entitled “Cultured turbulence, or inadequate oxygenation in conventional cell 
Normal Mammalian Tissue and Process”, filed May 25, culture systems. On a small scale, mammalian tumor cells 
1993, is a related application, and is also incorporated by have been grown in containers with small microwells to 
reference. 3o provide surface anchors for the cells. However, cell culture 
processes for mammalian cells in such microwell containers 
generally do not provide sufficient surface area to grow 
mammalian cells on a sufficiently large scale basis for many 
commercial or research applications. 
have been grown in 
culture systems to provide three-dimensional growth in the 
presence of a pre-established stromal support matrix. U.S. 
Pat. No. 4,963,489, Three-Dimensional Cell and Tissue 
Culture System, Naughton, et al., Oct. 16, 1990; U.S. Pat. 
4o No. 5,032,508, Three-Dimensional Cell and Tissue Culture 
System, Naughton, et al., Jul. 16, 1991. A biocompatible, 
The invention relates to the production of high-fidelity non-living material formed into a three-dimensional stmc- 
three-dimensional human urogenital tract carcinomas from a ture is inoculated with stromal cells, cases, the 
culture of carcinoma cells maintained in a fluid culture three-dimensional stmcture is a mesh pre-coated with col- 
media contained in a microgravity vessel. High-fidelitY 45 lagen. Stromal cells and the associated connective tissue 
three-dimensional human-urogenital tract carcinomas were proteins naturally secreted by the stromal cells attach to and 
also cultured from a coculture of normal cells inoculated envelop the three-dimensional stmcture, The interstitial 
with carcinoma cells in fluid media contained in a micro- spaces of the structure become bridged by the stromal cells, 
gravity vessel. which are grown to at least subconfluence prior to inocu- 
lating the three-dimensional stromal matrix with tissue- 
specific cells. 
ORIGIN OF THE INVENTION 
The invention described herein was made in the perfor- 
mance of work under a National Aeronautics and Space 
Administration (NASA) contract and is subject to the pro- 35 
visions of Section 305 of the National Aeronautics and 
Space Act of 1958, h b l i c  Law 85-568 (72 Stat, 435; 42 
U.S.C. 2457). 
Adenocarcinomas and 
FIELD OF THE INVENTION 
BACKGROUND OF THE INVENTION 
Cell culture processes have been developed for the growth Conventional culture processes have been utilized to 
of single cell bacteria, yeast and molds, which are resistant produce limited size and viability tumor cell aggregates. The 
to environmental stresses or are encased within a tough cell multicell tumor cell spheroids produced without attachment 
wall. Mammalian cell culture, however, is much more 55 substrates have been used to study cell and environmental 
complex because the cells are delicate and have complex interactions in tumors. Sutherland, R. M., “Cell and Envi- 
nutrient and other environmental requirements for maintain- ronmental Interactions in Tumor Microregions: The Multi- 
ing viability and cell growth. cell Spheroid Model”, 240 Science 177-184 (Apr. 8,1988). 
Large scale culture of bacterial-type cells is highly Such three-dimensional cell aggregates have been used for 
developed, and such culture processes are less demanding 60 studies of regulation of embrYologica1 development in a 
and less difficult to cultivate than mammalian cell cultures. variety of malignant cell types, including carci~omas. 
For example, bacterial cells can be grown in large volumes Collagen-coated cellulose sponges have been used to 
of liquid medium and can be vigorously agitated without any study three-dimensional growth of bladder cancer cells in 
significant damage. Mammalian cells, however, cannot vitro. Leighton, J., et al., “Development of Tissue Culture 
withstand excessive turbulent action without damage to the 65 Procedures for Predicting the Individual Risk of Recurrence 
cells. Mammalian cell cultures also require complex nutrient in Bladder Cancer”, 37 Cancer Res. 2854-59 (August 
media to support cell proliferation and growth. Additionally, 1977). The sponges allow carcinoma and other cancer-type 
3 
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cells to adhere, migrate, and proliferate on collagen sub- 
strates. Clinical tumor fragments are collected and a mince 
of tumor tissue placed in the sponge and the combination is 
embedded in a fibrin clot. The procedures for cultivating the 
carcinomas are complex and culture periods are limited due 
to degenerative changes which were found to begin to occur 
by the tenth day of culturing. Abaza, N. A,, et al., “Clinical 
Bladder Cancer in Sponge Matrix Tissue Culture- 
Procedures for Collection Cultivation, and Assessment of 
Viability, 42 (3) Cancer 1364-74 (Sept. 1978). 
Multicellular tumor spheroids of bladder cancer cell lines 
have been propagated using a microcarrier stirrer. Knuchel, 
R., et al., “Sensitivities of Monolayers and Spheroids of the 
Human Bladder Cancer Cell Line MGH-UI to the Drugs for 
Intravesical Chemotherapy”, 49 Cancer Res. 1397-1401 
(Mar. 15, 1989). The spheroids were initiated by inoculating 
a suspension of single cells into a medium-containing flask, 
and stirring the cells continuously over a predetermined 
period of time. The spheroids were grown to an average 
diameter of 0.7 mm, and used to study the cytotoxicities of 
drugs used for chemotherapy. Spheroids of larger sizes were 
not reported. 
Microcarrier beads have been developed for providing 
increased surface areas for cultured cells to attach and to 
provide conditions which allow cells to assemble into tissues 
which simulate the spatial three-dimensional form of actual 
tissues in the intact organism. Microcarrier beads with 
attached cultured cells require agitation in a conventional 
bioreactor vessel to provide suspension of the cells, distri- 
bution of fresh nutrients, and removal of metabolic waste 
products. To obtain agitation, such bioreactor vessels have 
used internal propellers or movable mechanical agitation 
devices which are motor driven so that the moving parts 
within a vessel cause agitation in the fluid medium for the 
suspension of the microcarrier beads and attached cells. 
Agitation of mammalian cells, however, subjects them to 
high degrees of shear stress which can damage the cells and 
limit ordered assembly of these cells according to cell 
derived energy. These shear stresses arise when the fluid 
media has significant relative motion with respect to vessel 
walls, impellers, or other vessel components. Cells may also 
be damaged in bioreactor vessels with internal moving parts 
if the cells or beads with cells attached collide with one 
another or vessel components. 
Coculture of tumor and normal cells in solid-state culture 
has been reported as shown in U.S. Pat. No. 4,352,887 to 
Reid et al., issued Oct. 5, 1982. However, the three- 
dimensional environment and culture did not achieve stan- 
dard clinical testing protocol, such that the three- 
dimensional environment is nurtured by a mixed-bed of 
tumor and normal cells. 
Three-dimensional tumor cell aggregates and growth pro- 
vide a unique system in which to simulate the conditions of 
clinical therapy in vitro. The three-dimensional arrangement 
of cells in vitro can permit various combinations of physical, 
chemical, and nutritional stress factors to be tested under 
conditions that resemble those of in vivo tumors. In vitro 
screening of chemotherapeutic agents may utilize three- 
dimensional carcinoma cell aggregates to determine the 
potential effectiveness of particular therapies and to identify 
the optimal therapeutic regimen for an individual patient. 
Three-dimensional tumor models may also provide a means 
for early identification of patients who can expect serious 
recurrence and those who are unlikely to have recurrent 
disease. 
Mammalian cell and tissue culture technology is essential 
to research concerning tumor genesis and tumor cell inva- 
siveness. Therefore, it is important that tumor models uti- 
lized in vitro mimic to the extent possible, in vivo properties 
of tumor cell lines. Although animal models are useful for 
studying carcinomas, many biochemical and molecular stud- 
s ies require that cells be grown in vitro. Studies on carcinoma 
cell lines have centered around the expression of oncogenic 
and protooncogenic markers and nucleotide sequences in 
order to elucidate the etiology of malignant transformation. 
Studies have led to insight and speculation as to the origin 
i o  of transformation, the genetics of transformation, and the 
treatment or inhibition of the transformation process. 
However, the models studied have lacked sufficient fidelity 
for adequate comparison of in vitro culture systems to 
observations in situ. In vitro tumor models have failed to 
is provide intact cell sub-populations, stable isoenzyme 
patterns, stable ploidy, stable and broad-based growth 
patterns, and high-fidelity expression of specific cellular 
proteins. Large scale, high-fidelity three-dimensional in 
vitro culture carcinoma models are necessary to studying 
20 developmental, mutagenic, metastagenic and transformation 
properties of carcinomas. 
SUMMARY OF THE INVENTION 
Aggregates of human urogenital tract carcinoma cells 
2s have been cultured in vitro without the presence of normal 
cells. Human urogenital tract is defined herein to include the 
bladder, prostate, kidney and associated tissues emanating 
from common embryological origins. Urogenital tract car- 
cinoma cells were introduced into a culture vessel contain- 
ing culture media and culture matrix. The carcinoma cells 
were cultured at microgravity conditions, whereby the car- 
cinoma cells formed cell aggregates. The microgravity con- 
ditions were maintained so that high-fidelity three- 
dimensional carcinoma growth was achieved from the 
Aggregates of human urogenital tract carcinoma cells 
were cocultured in vitro with normal mammalian cells. 
Normal mammalian cells were introduced into a culture 
4o vessel containing culture media and culture matrix. Uro- 
genital tract carcinoma cells were added to the culture vessel 
and the microgravity culture conditions maintained so that 
the cocultured normal cells and carcinoma cells achieved 
high-fidelity three-dimensional carcinoma growth. The nor- 
4s mal cells were cultured at microgravity conditions until the 
cells reproduced to form aggregates. 
The aggregates were produced under “microgravity cul- 
ture conditions” which can be microgravity or simulated 
microgravity. Simulated microgravity was created in unit 
50 gravity by modulating the horizontal rotation of a culture 
vessel completely filled with culture media containing a 
culture matrix with normal mammalian cells and urogenital 
tract carcinoma cells or only the carcinoma cells. In the 
preferred process, simulated microgravity was produced in 
5s a horizontally rotating wall culture vessel by the simulta- 
neous conditions of (1) collocation of cells and culture 
matrix with similar or differing sedimentation properties in 
a similar spatial region, (2) freedom for three dimensional 
spatial orientation of cell aggregates formed by the culturing 
60 of the cells, and (3) low shear and essentially no relative 
motion of the culture environment with respect to the walls 
of the culture vessel. The culture conditions included mass 
transfer under microgravity conditions with exchange of 
nutrients for metabolic waste and appropriate gas exchange 
The process for producing the urogenital tract carcinoma 
cell aggregates is particularly unique in that the resultant 
30 . 
3s monoculture. 
65 in the culture system. 
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product is a cell aggregation of a size of 4 millimeters and 
larger. The size of the cell aggregations is significant because 
assembly of the three-dimensional masses of this size is not 
possible without the complex functional interrelationship of 
in situ urogenital tract carcinomas. 
High-fidelity three-dimensional urogenital tract carcino- 
mas were produced artificially by culturing urogenital tract 
carcinoma cells in a vessel containing culture media and a 
culture matrix, preferably of generally spherical microcar- 
riers. The vessel is capable of culturing at microgravity 
culture conditions. The carcinoma cells were preferably 
dissociated prior to introduction into the culture vessel. 
Tissue engineering was employed by selectively introducing 
urogenital tract carcinoma cells and culture matrix into the 
vessel and then culturing the cells at microgravity culture 
conditions. The carcinoma cells were cultured under micro- 
gravity conditions whereby high-fidelity three-dimensional 
carcinoma growth was achieved. 
The cultured and cocultured carcinoma cell aggregates 
exhibited three-dimensional growth, intact cell subpopula- 
tions of differentiated and undifferentiated cells, stable 
isoenzyme patterns, stable ploidy, stable and broad-based 
cell growth patterns and high-fidelity expression of specific 
cellular proteins, such as proteoglycan. Specific protein 
markers, such as Prostate Specific Antigen (PSA) and Pro- 
static Acid Phosphatase (PAP) were also expressed. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is an SEM (scanning electron microscopy) at 91 
hours of a cultured high-fidelity three-dimensional bladder 
carcinoma cell aggregation at 350x magnification. 
FIG. 2 is an SEM of the cells in FIG. 1 at 1500x 
magnification. 
FIG. 3 is an SEM at 381 hours of a cultured high-fidelity 
three-dimensional bladder carcinoma cell aggregation at 
350x magnification. 
FIG. 4 is an SEM of the cells of FIG. 3 at 1500x 
magnification. 
FIG. 5 is an SEM at 570 hours of cultured high-fidelity 
three-dimensional bladder carcinoma cell aggregates at 
200x magnification. 
FIG. 6 is an SEM of the cells of FIG. 5 at 1500x 
magnification. 
DETAILED DESCRIPTION OF THE 
INVENTION 
Aggregates of human urogenital tract carcinoma cells 
were cultured in vitro to produce artificial high-fidelity 
three-dimensional carcinomas. The artificially-produced 
carcinoma masses exhibited intact cell subpopulations of 
differentiated and undifferentiated cells, stable isoenzyme 
patterns, stable ploidy, stable and broad-based cell growth 
patterns and high-fidelity expression of specific cellular 
proteins, specifically proteoglycan. Specific protein 
markers, such as Prostate Specific Antigen (PSA) and Pro- 
static Acid Phosphatase (PAP) were also expressed. 
Examples of human urogenital tract carcinomas cultured 
using the method of the present invention are described 
below. 
Artificially-produced high-fidelity three-dimensional 
human prostate carcinomas were propagated from carci- 
noma cells obtained from a human prostate carcinoma. The 
prostate carcinoma cell lines propagated, designated PC3 
and LnCap by convention, are primarily undifferentiated 
prostate carcinoma cell lines. Both prostate carcinoma cell 
5 
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lines are a mixed-bed carcinoma having a mixture of stan- 
dard cell subpopulations. The carcinoma cell lines were 
obtained from American Type Culture Collection (ATCC, 
Rockville, Md.). The PC3 cells were ATCC no. CRL-1435 
and the LnCap were ATCC no. CRL-1740. Both cell lines 
were successfully propagated according to the methods 
described herein. Carcinoma cells may also be obtained 
directly from the organ of carcinoma origin, or the organ of 
metastases. 
In the preferred embodiment of the present invention, 
carcinoma cells were cocultured with normal human cells. 
The normal cells selected were normal adult prostate fibro- 
blasts established from primary cultures from the normal 
prostate of organ donors. The normal fibroblasts were 
obtained from Clonetics Corporation (San Diego, Calif.). It 
is preferred that the fibroblasts selected be specific to the 
organ of interest. 
The prostate carcinoma cells and the normal prostate 
fibroblasts were initiated and propagated separately in 
T-flasks containing a preferred culture media designated 
GTSF-2. A preferred formulation for GTSF-2 media is 
provided in Table 1 below. 
The carcinoma cells and the fibroblasts were grown in 
monolayer culture. GTSF-2 was found to meet the growth 
requirements of the monolayer cultures, and the subsequent 
culture vessel system, without the need for unique growth 
factors and other complex components found in other media. 
The GTSF-2 media is a tri-sugar-based medium containing 
the sugars: glucose, galactose and fructose supplemented 
with 7% fetal bovine serum (FBS). The pH of the media was 
adjusted to 7.4 with 1N NaOH. 
TABLE 1 
Tri-Sugar Based Medium 
GTSF-2 
SourceiOrder 01 
Component Concentration Designation 
MEM-alpha 
supplemented with 
2.25 gmiL NaHCO, 
L-15 
NaHCO, 
HEPES 
Folic acid 
0.05% Nicotinic acid 
Bactopeptone 
i-Inositol 
Fructose 
Galactose 
D-Glucose 
300 mM L-Glutamine 
Gentamycin 
Fungizone 
Insulin-transferrin- 
sodium-solenite 
Fetal bovine serum 
400 ml (40%) 
600 ml (60%) 
1.35 giliter 
3. giliter 
6.667 pgiliter 
0.667 mliliter 
0.6 giliter 
0.024 giliter 
0.13 giliter 
0.25 giliter 
1.0 giliter 
10 mliliter 
1 mliliter 
2 mliliter 
5 mliliter 
70 ml (7%) 
GIBC01430-1300EB 
Sigmais-5761 
Research Or- 
ganicsi6003H-2 
SigmaiF-8758 
SigmaiN-4126 
Difcoi0118-01 
SigmaiI-5125 
SigmaiF-3510 
SigmaiG-5388 
SigmaiG-5250 
SigmaiG-5763 
GIBC0/600-5750AD 
GIBC01600-5295AE 
SigmaiI-1884 
HycloneiA-1111-L 
The monolayer cell cultures were maintained in a humidi- 
fied CO, Forma incubator in 5% C0,:95% air constant 
atmosphere, and 98% humidity at a temperature of 37" C. 
When glucose in the cell culture media was depleted to 
2&60 mgidl, 50 to 100% of the culture media was replaced. 
Cell cultures were expanded when cells became confluent on 
the bottom of the T-flasks. Standard enzymatic dissociation 
with a solution of 0.1% Trypsin, 0.1% EDTA, in phosphate- 
buffered saline (PBS) solution for 15 minutes at 37" C., was 
used to separate the cells. 
Once the concentration of normal and carcinoma cells 
grown in monolayer culture was sufficient to provide the 
5,851,816 
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desired cell concentration for seeding into the culture vessel, Culture conditions included mass transfer with exchange 
the carcinoma cells and the normal fibroblasts were removed of nutrients for metabolic waste and appropriate gas 
from the T-flasks. The cells were removed by enzymatic exchange in the culture system. The culture medium was 
digestion with 0.1% Trypsin, 0.1% EDTA, for 15 minutes at changed in response to glucose depletion. Fresh medium 
37" c.2 and washed Once with calcium- and magnesium-free s was replenished by 50% of the total vessel volume each 20 
PBS (CMF-PBS). The cells were assayed for viability using to 24 hours, 
Trypan Blue stain exclusion (GIBCO). The cells were cen- 
trifuged at 800xG for 10 minutes in conical 15-ml centrifuge 
tubes in GTSF-2 with 7% FBS, The cells were then resus- 
48 hours Of the preferred primary 
Of monodispersed 'Orma' human prostate fibre- 
pended in fresh medium and diluted into Corning T-flasks blasts formed visible three-dimensional cellular aggregates. 
with 25 ml of fresh growth medium, Cells were held on ice 10 The fibroblast aggregates were maintained in solution 
in fresh growth medium until inoculation into a culturing through rotation of the RWV at 25 rpm. The fibroblasts were 
vessel. The carcinoma cells and the normal fibroblasts cells allowed to become confluent such that the beads were 
were kept separate during preinoculation procedures. entirely covered before a coculture inoculum of 2x10' 
the preferred method, the primary inoculum of mono- prostate carcinoma cellsiml was added to the culture vessel, 
dispersed normal cells introduced into the culture vessel was resulting in a coculture of Prostate c a r c i m ~ ~ ~  cells and 
4x10' normal prostate fibroblast cellsiml in the 110-ml normal cells. Although normal prostate fibroblasts were 
volume vessel, with 5 mg/ml (550 mg total) Cytodex-3 selected as the primary inoculum in the preferred 
microcarrier beads (Pharmacia, Piscataway, N.J.). embodiment, normal prostate mesenchymal cells, initiated 
Cytodex-3 microcarriers were Type I, collagen-coated dex- and propagated as described herein for normal fibroblasts, 
tran beads, 175 microns in diameter. After the primary 20 may form the primary inoculum, inoculated at 4x10' normal 
inoculum was prepared for seeding, it was transferred to a mesenchyme cells/ml, 
The coculture process described allows carcinoma tissues media and cultured at microgravity conditions. Rotation to be engineered, or constructed, through the control of speed in the vessel was initially set at a rate of 12-14 rpm. culture conditions and the introduction of cells. Tissue 
monodispersed prostate carcinoma cells was introduced into of the results of the culture system by introducing various the culture vessel at 2x10' cellsiml in the 110 ml volume 
points during the culturing process to obtain the desired above for the preferred embodiment. 
primary inoculum of monodispersed normal cells may be In an alternate embodiment, the monodispersed carci- 
introduced into the culture vessel at 4x10' normal prostate noma cells formed visible cellular aggregates at approxi- 
fibroblast cells/ml with an inoculum of 2x10' prostate mately 72 hours Post inoculation. The Prostate cell aggre- 
carcinoma cells/ml with 5 mg/ml Cytodex-3 microcarrier gates were maintained through rotation of the RWV at 25 
beads described above. Thereby, a coculture of prostate 35 ITm. The Prostate aggregates were maintained as a 
carcinoma cells and normal prostate fibroblasts will be monoculture of prostate carcinoma cells. This culturing 
present in the vessel at the initiation of culturing. process also allows carcinoma tissues to be engineered, or 
The microgravity conditions were simulated in unit grav- constructed, through the control of culture conditions and 
ity by a horizontal rotating wall vessel (RWV) for both the the introduction Of 
preferred and alternate embodiments of the invention. A 40 In the Preferred embodiment and an alternate 
preferred horizontal rotating wall vessel (RWV) bioreactor embodiment, cellswere allowed to grow until the aggregates 
is described in U.S. Pat. No. 5,153,131, Wolf et al., issued exceeded 4 mm in diameter (approximately 11 to 15 days) 
Oct. 6, 1992, and is incorporated by reference herein. The with minimal necrosis. When the aggregates reached the 
horizonta~~y rotating wall vessel described in u,s, pat, N ~ ,  desired size, viable cell samples were harvested over periods 
5,026,650, Schwarz et al., issued Jun. 25, 1991, and incor- 45 of 3 to 4 days, and Prepared for the following discussed 
porated herein by reference may also be used to culture analyses. Higher cell densities were observed with cocul- 
high-fidelity three-dimensional urogenital tract carcinoma tured carcinoma cells than with the carcinoma cells cultured 
cells, The rotation of the culture vessel (bioreactor) was alone. Under the microgravity conditions, the carcinoma and 
modulated to produce the simultaneous conditions of (1) normal cells were observed to express morPhologica1 and 
co~~ocation of cells and culture matrix with similar or biochemical characteristics found in carcinoma cells in situ, 
differing sedimentation properties in a similar spatial region, and achieved three-dimensional cellular aggregates of up to 
(2) freedom for three dimensional spatial orientation of 5 mm in diameter. 
tissues formed by the culturing of the cells and (3) low shear The assessment of fidelity of the carcinoma cell aggre- 
and essentially no relative motion of the culture environment gates was based upon the regulation of specific oncogene 
with respect to the walls of the culture vessel. 55 markers and protein markers. The assessment of fidelity 
during culturing. The speed of the rotation of the culture chemical characteristics of the aggregates were &served 
vessel was increased if the cell aggregates fell excessively using scanning electron microscoPY and histology. Samples 
inward and downward on the downward side of the rota- from R w v  cultures were taken at multiple time points 
tional cycle and excessively outward and insufficiently 60 throughout the course of the culturing procedures for histo- 
upward on the upgoing side of the rotational cycle to prevent logic analysis (approximately 72 hours Post i~oculation and 
wall impact. The rotation of the culture vessel was decreased then every 72 hours). Standard immunostaining Procedures, 
in response to excessive accumulation of tissue aggregation including antibodies specific to vimentin, keratin, and 
near the outer wall of the culture vessel SO as not to restrict cytokeratin, were also utilized to evaluate differentiation and 
three dimensional growth. As the tissue aggregates grew, the 65 the Presence of cellular components. 
rotation was adjusted to obtain minimal collision frequency Two basic stains were performed on 20, 10, and 6-pm 
and intensity. aggregate sample sections: hematoxylin and eosin (H&E) 
with GTSF-2 with 7% FBS 
In an embodiment? a primary 
Of the 25 engineering of carcinoma growth enables the manipulation 
with 5 mg/ml Cytodex-3 micro-carrier beads, as described carcinoma types into the system at different 
In yet another embodiment of the present invention, a 30 growth and aggregate size. 
The trajectory of the cell aggregates was determined relates to the in situ environment. Morphological and bio- 
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and mucicarmine staining. After removal from the reactor lows: 20% for 5 minutes; 50% for 5 minutes; 75% for 5 
vessels, samples were washed once with calcium-and minutes; 95% for 5 minutes; 100% twice for 5 minutes each 
magnesium-free PBS. The samples were suspended in a time. 
buffer containing 3% glutaraldehyde and 2% paraformalde- Samples were dried by dehydration with hexamethyldisi- 
hyde in 0.1M cacodylate buffer at pH 7.4. Samples of the 5 lazane (HMDS) (Electron Microscopy Sciences). After 
cocultured prostate carcinoma cell aggregates and the transfer to HMDS, samples were allowed to soak for 10 
monocultured prostate cell aggregates were analyzed by minutes, drained, and air dried overnight. Dried samples 
standard histology and electron microscopy techniques were sprinkled with a thin layer of silver paint on a specimen 
(Histologic Staining Methods, Armed Forces Institute of stub, dried, coated by vacuum evaporation with platinum- 
Pathology, American Registry of Pathology, 3rd.ed. New palladium alloy, and then examined in a scanning electron 
York, London, 1968). microscope at an accelerating voltage of 5 to 10 kV. 
Mucicarmine staining was performed according to the Micrographs taken of 3 to 5 day cultures showed sub- 
procedure of Sheehan and Hrapchak (Theory and practice of stantial coverage of the microcarriers by three-dimensional 
~ i s t o t e c ~ n o ~ o g y ,  2nd,ed, s t ,  b u i s ,  1980). ~i~~~~~ were prostate carcinoma cell aggregates. Microcarriers were uni- 
fixed as previously stated. The samples were embedded in 1~ formly 'Overed with aggregates by l1 t' l5 days Of 
paraffin, blocked, and cut in multiple thicknesses. Sections 
rations were stained with Weigert's iron hematoxylin work- noma cells cultured in T-flasks and a cDNA library created 
ing solution for 5 minutes, then rinsed with running tap from cocultured prostate carcinoma cells cultured in a 
water for 5 minutes and placed in mucicarmine working 2o rotating wall vessel were used in a subtractive hybridization 
solution for 30 minutes at temperature, slides were process to identify mRNAof specific expressions associated 
then rinsed with deionized water, stained with tartrazine with the particular culture environment. Oncogenic markers 
water. The slides were dehydrated with zylene and mounted by the method Of Pardee and Of mRNA. 
The subtractive hybridization process used to create the 
Results of staining showed the cocultured and cultured cDNA libraries is a standard, commercially available tech- 
prostate carcinoma cell aggregates to exhibit intact cell nology (Invitrogen). A C-has/bas-l probe was 
subpopulations of differentiated and undifferentiated cells. 'pecific mRNA expression. 
Cellular structures, such as microvilli, were observed. The 
cellular protein, proteoglycan, was specifically identified in 30 isoenzymes were Observed and determined to be 
in the 
were then mounted on slides and deparaffinized, The preps- A cDNA library created from cocultured prostate carci- 
solution for 1 to 5 seconds, then rinsed again with deionized known to be specific for the cell types studied were analyzed 
for 
for analysis. 2s 
to 
By separation Of mRNA and DNA, basic patterns Of 
the cells of the three-dimensional aggregates, Protein Protein markers, PSA and PAP, which are specific markers 
markers, Prostate Specific Antigen (PSA) and Prostatic Acid for prostate tumors, were expressed. ploidy was 
Phosphatase (PAP), were observed in the prostate carcinoma demonstrated. The Oncogene markers and protein markers 
cell aggregates. form a basis for assessing fidelity and comparing transitions 
electron microscopy at the Same time as those taken for dimensional cultures grown as cocultures and monocultures 
in the RWV. histological analysis. After removal from the reactor vessels, 
samples were washed once with CMF-pBs. The samples A CDNA library was also created for the monocultured 
placed in temperature cacodylate buffer and postfixed 4o monocultured cells cultured in the rotating wall vessel using 
according to the standard procedures described, ~~~h the same technology described for the cocultured cell culture 
sample was then in a modified BEEM capsule ( s p ~ ,  cDNAlibraries. Similar results at the cellular and molecular 
West Chester, N.Y.). (The capsules were modified by remov- level were Observed. 
ing the caps from two capsules, discarding the extra capsule, The assessment of carcinoma cell aggregate fidelity may 
and slicing the conical ends off of the remaining capsule 45 also be based upon the ability of the aggregates to withstand 
with a scalpel, Ahole was then punched in each cap, ~4 cm2 successful transplantation into nude mouse models. The 
square of 50pm polyester mesh (Tetko, Inc., Briarcliff, N.Y.) cocultured and ~onocultured Prostate carcinoma cell aggre- 
was Over one open end of the capsule and a hole- gates will provide high-fidelity three-dimensional prostate 
punched cap attached to the end.) Once the sample was carcinoma masses Providing tumor models that closely 
placed in the modified capsule, a 4 cm2 of 50 pm polyester SO resemble the carcinoma in situ. 
mesh was placed Over the remaining open end and a hole- Standard surgical transplantation procedures may be used 
punched cap attached. Each capsule was then placed in a 50 to transfer cellular samples of the three-dimensional cocul- 
(Electron Microscopy Sciences, Fort Washington, Pa.) standard surgical transplantation procedures. The transplants 
added to each tube. The samples were allowed to fix for 5s can be observed in parallel with controlled transplants of 
45-60 minutes with the tube covered with aluminum foil. T-flask grown cocultured carcinoma cell aggregates. 
Samples were then rinsed thoroughly with Milli-Q ultrapure It has been observed elsewhere that controlled transplants 
water (Millipore Corp., Bedford, Mass.). Filtered 1% soh-  of cocultured carcinoma cells grown in T-flasks do not 
tion of thiocarbohydrazide (TCH) (Electron Microscopy achieve successful transplantations into nude mice. It is 
Sciences) was then added at approximately 10 ml to each 60 predicted that the cocultured cell aggregates grown in the 
tube and allowed to fix for 10 minutes with the tube covered rotating culture vessel, however, will continue to develop 
with aluminum foil. The samples were then washed for 5 and grow into larger tumors following transplantation into 
minutes with Milli-Q five times and fixed with 10 ml 1% the nude mouse. The success of cell aggregate transplanta- 
buffered osmium tetroxide for 10 minutes while swirling the tion and evidence of continued tumor growth in the mouse 
tube covered with aluminum foil. Samples were then rinsed 65 will further demonstrate the high-fidelity characteristic of 
with Milli-Q four times for 5 minutes each time, and the cocultured three-dimensional prostate carcinoma cell 
dehydrated with increasing concentrations of EtOH as fol- aggregates. 
Samples from the RWV cultures were taken for scanning 35 from grown in T-flasks to the high-fidelity three- 
were fixed as previously stated. The samples were then aggregates in T-flasks and a library created for 
ml tube and approximately 10 ml 1% osmium tetroxide t u r d  carcinoma cell aggregates to a nude mouse using 
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Similarly, transplants of the prostate carcinoma cell The scale bar in FIG. 3 provides a measure of 50 pm. FIG. 
aggregates grown in the RWV without the presence of 4 is an SEM of the cells of FIG. 3 at 1500x magnification 
normal cells may be transferred to a nude mouse and at 381 h. Extensive microvilli development 40 at the surface 
observed in parallel with controlled transplants of T-flask of the cells is evident. The scale bar in FIG. 4 provides a 
grown cocultured carcinoma cell aggregates. The ability of 5 measure of 10pm. FIG. 5 is an SEM of cultured high-fidelity 
cell aggregates to transfer successfully into the mouse three-dimensional bladder carcinoma cell aggregates at 
models will be indicative of the high-fidelity characteristic 200x magnification after 570 hours of culturing. The scale 
of the three-dimensional cell aggregates cultured in the bar in FIG. 5 provides a measure of 100 pm. FIG. 6 is an 
rotating wall vessel. SEM of the cells of FIG. 5 at 1500x magnification. Com- 
Artificially-produced human bladder carcinomas were plete confluence and carcinoma cell aggregate formation is 
also propagated from carcinoma cells obtained from a evident. Enhanced microvilli formation 60 and proteoglycan 
human bladder carcinoma. The bladder carcinoma cell line secretion 62 (at arrowhead) are apparent. The cells are 
propagated, designated T-24 by convention, is a primarily expressing morphologic and biochemical characteristics 
undifferentiated human bladder carcinoma cell line. The found in carcinoma cells in situ. The scale bar in FIG. 6 
T-24 cell line is a mixed-bed carcinoma having a mixture of 1s provides a measure of 10 pm. 
standard T-24 cell subpopulations. The bladder carcinoma The examples included are not intended to limit the scope 
cells were obtained from ATCC no. HTB 4. In the preferred of the present invention. Human urogenital tract carcinoma 
embodiment of the inventive process, carcinoma cells were cells have been cocultured with normal urogenital tract cells 
cocultured with normal human cells. The normal human to produce aggregates of cells of high-fidelity three- 
cells were normal human bladder fibroblasts established 2o dimensional carcinoma masses. Human urogenital tract car- 
from primary cultures from the normal bladders of organ cinoma cells have also been monocultured to produce high- 
donors. The normal human bladder fibroblast cell line was fidelity three-dimensional carcinoma masses. Other 
also obtained from Clonetics. substitutions, modifications and variations are apparent to 
The Same procedures and techniques described herein those skilled in the art without departing from the disclosure 
with reference to the culturing of human prostate carcinoma 2s and scope of the invention. 
cells were followed to prepare high-fidelity three- What we claim is: 
dimensional human bladder carcinoma cell aggregates 1. A process for producing aggregates of urogenital tract 
resembling carcinomas found in situ. Bladder carcinoma 
cells were cocultured or monocultured as described. Fol- (a) inoculating urogenital tract carcinoma cells into a 
lowing culturing, the bladder carcinoma cell aggregates 30 culture vessel containing culture media and a culture 
were analyzed as described above for prostate carcinomas. matrix; 
Similar characteristics of intact cell subpopulations of dif- (b) culturing the urogenital tract carcinoma cells under 
ferentiated and undifferentiated cells, stable isoenzyme microgravity conditions whereby the urogenital tract 
patterns, stable ploidy, stable and broad-based cell growth carcinoma cells form aggregates; and 
patterns and high-fidelity expression of specific cellular 35 (.) maintaining the microgravity culture conditions 
proteins, specifically proteoglycan, were observed with the whereby high-fidelity, three-dimensional urogenital 
bladder carcinoma cell aggregates as with the prostate tract carcinoma growth is achieved. 
carcinoma cells. The cocultured and monocultured human 2, ne process for producing aggregates of urogenital 
bladder carcinoma cell aggregates were found to be high- tract carcinoma cells of claim 1, wherein the carcinoma cells 
fidelity three-dimensional bladder carcinoma masses that 40 are a mixture of carcinoma cell subpopulations selected 
Provide tumor models that closely resemble the bladder from the group consisting of prostate carcinoma, bladder 
carcinoma in situ. carcinoma, and kidney carcinoma. 
Scanning electron microscopy (SEM) views of T-24 blad- 3. The process for producing aggregates of urogenital 
der carcinoma cells monocultured and grown on microcar- tract carcinoma cells of claim 1, wherein the culture media 
rier beads in the RWV are shown in FIGS. 1-6. (The kV 4s comprises fetal bovine serum and a tri-sugar based medium. 
reference on the Figures pertain to the voltage of the SEM. 4. A process for producing aggregates of urogenital tract 
The SEM sequence number and magnification powers are carcinoma cells of claim 3 wherein the tri-sugar based 
also present in the Figures.) FIG. 1 is an SEM of a cultured medium includes mixtures of the group consisting of 
high-fidelity three-dimensional bladder carcinoma cell fructose, galactose and glucose. 
aggregation at 3.50~ magnification after 91 hours of cultur- so 
ing in the vessel in microgravity conditions. Confluent tract carcinoma cells of claim 1, wherein the microgravity 
microcarriers and aggregate formation are seen. Individual culture conditions are created by the culture vessel. 
cells generally indicated at reference numeral 10 can be 6. The aggregates of urogenital tract carcinoma cells 
distinguished. The three-dimensional aggregates are form- produced by the process of claim 5. 
ing intact cell subpopulations of differentiated and undiffer- 5s 7. The process for producing aggregates of urogenital 
entiated cells. The size of the carcinoma cells and aggregates tract carcinoma cells of claim 1, wherein microgravity 
can be determined by the scale bar present on each Figure. culture conditions are simulated. 
The scale bar in FIG. 1 provides a measure of 50 pm. FIG. 8. The process for producing aggregates of urogenital 
2 is an SEM of the cells in FIG. 1 at 1.500~ magnification at tract carcinoma cells of claim 1, wherein the urogenital tract 
91 h. The greater magnification produces a “fuzzy” appear- 60 carcinoma cells are selected from the group consisting of 
ance of the cells, due to the microvilli of the cells at 20. The prostate carcinoma, bladder carcinoma, and kidney carci- 
scale bar in FIG. 2 provides a measure of 10 pm. noma. 
FIG. 3 is an SEM of a cultured high-fidelity three- 9. The process for producing aggregates of urogenital 
dimensional bladder carcinoma cell aggregation at 350x tract carcinoma cells of claim 1, wherein the microgravity 
magnification after 381 hours of culturing. Enhanced aggre- 65 culture conditions are created by having a horizontally 
gate formation and cell growth can be seen. Cell growth is rotating culture vessel in unit gravity producing the simul- 
stable and broad-based growth patterns are demonstrated. taneous conditions of (1) collocation of cells and culture 
carcinoma cells comprising the steps of 
5 .  The process for producing aggregates of urogenital 
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matrix with similar or differing sedimentation properties in 17. The process for producing aggregates of urogenital 
a similar spatial region, (2) freedom for three dimensional tract carcinoma cells of claim 12, wherein the urogenital 
spatial orientation of tissues formed by the culturing of the tract carcinoma cells are a mixture of carcinoma cell sub- 
cells and (3) low shear and essentially no relative motion of popu~ations, 
the culture environment with respect to the walls of the 5 18, The process for producing aggregates of urogenital culture vessel. tract carcinoma cells of claim 12, wherein the culture media 10. The aggregates of urogenital tract carcinoma cells 
comprises fetal bovine serum and a tri-sugar based medium. produced by the process of claim 9. 
11. The aggregates of urogenital tract carcinoma cells 19. A Process for Producing aggregates of urogenital tract 
produced by the process of claim 1. carcinoma cells of claim 18 wherein the tri-sugar based 
12. Aprocess for producing aggregates of urogenital tract lo medium includes mixtures of the group consisting of 
carcinoma cells comprising the steps of fructose, galactose and glucose. 
(a) inoculating normal mammalian cells into a culture 20. The process for producing aggregates of urogenital 
vessel containing culture media and a culture matrix; tract carcinoma cells of claim 12, wherein the microgravity 
(b) inoculating urogenital tract c a r c i m ~ ~ ~  cells into the 15 culture conditions are created by the culture vessel. 
culture vessel; 21. The aggregates of urogenital tract carcinoma cells 
(c) co-culturing the normal mammalian cells and the produced by the process of claim 20, 
tract carcinoma cells of claim 12, wherein the microgravity 
tract carcinoma under microgravity 22, The process for producing aggregates of urogenital 
conditions; and 
(dl maintaining the microgravity conditions culture conditions are created by simulating microgravity, 
whereby high-fidelity, three-dimensiona1 2o 23, A process for producing aggregates of urogenital tract tract carcinoma growth is achieved. carcinoma cells of claim 12, wherein the microgravity 13. The process for producing aggregates of urogenital culture conditions are created by having a horizontally tract carcinoma cells of claim 12, wherein step (a) further 
comprises culturing the normal mammalian cells under rotating culture vessel in unit gravity producing the simul- 
microgravity conditions whereby the normal mammalian 25 taneous conditions of (1) collocation of cells and culture 
cells form aggregates. matrix with similar or differing sedimentation properties in 
14, The process for producing aggregates of urogenital a similar spatial region, (2) freedom for three dimensional 
tract carcinoma cells of claim 12, wherein the normal spatial orientation of tissues formed by the culturing of the 
mammalian cells are fibroblasts. cells and (3) low shear and essentially no relative motion of 
15. The process for producing aggregates of urogenital 30 the culture environment with respect to the walls of the 
tract carcinoma cells of claim 12, wherein the normal culture vessel. 
mammalian cells are mesenchymal cells. 24. The aggregates of urogenital tract carcinoma cells 
16. The process for producing aggregates of urogenital produced by the process of claim 23. 
tract carcinoma cells of claim 12, wherein the urogenital 25. The aggregates of urogenital tract carcinoma cells 
tract carcinoma cells are selected from the group consisting 35 produced by the process of claim 12. 
of prostate carcinoma, bladder carcinoma, and kidney car- 
cinoma. * * * * *  
